Lecture 14: Antiphospholipid Antibody Syndrome
Shruti Chaturvedi, MBBS, MS
Presentation Date:
January 8, 2026
Antiphospholipid Antibody Syndrome:
> A pro-thrombotic syndrome:
Clinically syndrome, associated with arterial and/or venous thrombosis, and or pregnancy complications.
> Laboratory features: Lupus Anticoagulant, and/or antibodies to beta-2-glycoprotein-1 or cardiolipin.
> Despite decades of clinical research and experience, the pathophysiology remains subject to debate.
Shruti Chaturvedi, MBBS, MS
Johns Hopkins School of Medicine
Baltimore, MD, USA
schatur3@jhmi.edu
Disclosures for Shruti Chaturvedi MBBS > Consulting – Takeda, Alexion, Sanofi, Novartis, RallyBio, TargED
> Consulting, research support (to institution) – Sanofi, Takeda, Sobi
> Membership on advisory committee / steering committee – Sobi, Alexion, Sanofi, Novartis, Takeda
> Membership on board of directors: Hemostasis and Thrombosis Research Society, USTMA Consortium
> Royalties – UpToDate.com
Learning objectives: At the end of this presentation, the learner will be able to
Apply updated clinical and laboratory tools for the diagnosis of APS
Identify evidence-based strategies for the treatment of thrombotic APS
Identify pathogenic mechanisms and therapeutic targets for refractory and catastrophic APS
Image: C. Lockard Conley, founder of the Division of Hematology at the Johns Hopkins School of Medicine, first described the "Lupus Anticoagulant," an in vitro factor that interfered with coagulation in vitro, but was not associated with bleeding.